Novartis and IPCA Financial Analysis

Financial Analysis & NOVARTIS IPCA

Management Discussion & Analysis Overview of Indian Pharma Market ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Management Discussion & Analysis Overview of Indian Pharma Market

Management Discussion & Analysis Novartis Performance Overview Rs / Crores

[object Object],[object Object],[object Object],Management Discussion & Analysis Novartis Performance Overview

Management Discussion & Analysis IPCA Performance Overview

Management Discussion & Analysis IPCA Performance Overview Verticals 2006 (Crs) 2005 (Crs) Formulations 501.29 447.59 API & Intermediates 247.76 228.68 Net Total Sales 749.05 676.27

Company Novartis Ipca (Rs. / Crores) 2006 2005 2006 2005 SOURCE OF FUNDS Shareholders Funds 338 284 370 326 Loan Funds 6 7 197 221 Provision for Deferred Taxation (net) 48 43 Total 344 291 615 590 APPLICATION OF FUNDS Fixed Asset 10 22 374 323 Investments 7 48 4 3 Deferred Taxation 11 9 Current Assets: 449 329 358 361 Less : Current Liabilities 133 116 121 97 Net Current Assets 316 213 237 263 Pre-Operative Expenses (w/off) 0 Total 344 291 615 590

Novartis : Profit and Loss Account

IPCA : Profit and Loss Account

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Significant Accounting Policies IPCA

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Significant Accounting Policies IPCA

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Significant Accounting Policies Novartis

Ratio Analysis ,[object Object],[object Object],[object Object],[object Object],[object Object]

Leverage Ratios ,[object Object],[object Object],1. Debt Equity Ratio (Rs. In Crores) Novartis Ipca Year 2006 2005 2006 2005 Long Term Debt 6 7 197 221 Shareholders Equity 338 284 371 326 Debt-Equity Ratio 0.02 0.02 0.53 0.68

Leverage Ratios ,[object Object],[object Object],2. Debt Ratio (Rs. In Crores) Novartis Ipca Year 2006 2005 2006 2005 Long Term Debt 6 7 197 221 Total Assets 344 291 615 590 Debt Ratio 0.02 0.02 0.32 0.37

[object Object],[object Object],3. Interest Coverage Ratio Leverage Ratios (Rs. In Crores) Novartis Ipca Year 2006 2005 2006 2005 Net Profit * 146 102 60 83 Interest 3 2 14 11 Interest Coverage Ratio 48.67 51.00 4.29 7.55

[object Object],[object Object],Summary of Leverage Ratios Leverage Ratios Leverage Ratios Novartis Ipca 2006 2005 2006 2005 Debt-Equity Ratio 0.02 0.02 0.53 0.68 Debt Ratio 0.02 0.02 0.32 0.37 Interest Coverage Ratio 48.67 51.00 4.29 7.55

[object Object],[object Object],Profitability Ratios

3. Return on Capital Employed 4. Net Profit Ratio Profitability Ratios

[object Object],[object Object],[object Object],Summary Profitability Ratios

[object Object],[object Object],Liquidity Ratios

[object Object],[object Object],[object Object],Liquidity Ratios Summary

[object Object],[object Object],1. Total Assets Turnover Turnover Ratios

[object Object],[object Object],2. Fixed Assets Turnover Turnover Ratios

3. Inventory Turnover Ratio 4. Debtors Turnover Ratio Turnover Ratios

Summary ,[object Object],[object Object],[object Object],Turnover Ratios

[object Object],Turnover Ratios Company ( Rs / Crores) Novartis Ipca Year 2006 2005 2006 2005 Final Dividend 47.9 32 7.5 7.5 No of Shares (Crores) 3 3 2.5 2.5 Dividend per Share 15 10 3 3 Dividend per Share 15 10 3 3 Market Price per Share 595 503 368 371 Dividend Yield % 2.52% 1.99% 0.82% 0.81% Final Dividend 47.9 32.0 7.5 7.5 Net Profit 108 65 62 71 Dividend Payout % 44.43% 49.08% 12.19% 10.55%

Summary of Ratio Analysis ,[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],Summary of Ratio Analysis

Novartis and IPCA Financial Analysis

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Similar a Novartis and IPCA Financial Analysis

Similar a Novartis and IPCA Financial Analysis (20)

Más de Shahzad Khan

Más de Shahzad Khan (20)

Último

Último (20)

Novartis and IPCA Financial Analysis